Novartis Radioligand Therapy Lutathera FDA Approved First Medicine Specifically For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors
Portfolio Pulse from Benzinga Newsdesk
Novartis has received FDA approval for Lutathera, the first medicine specifically designed for pediatric patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The approval is based on the NETTER-P trial, which showed Lutathera has a consistent safety profile and comparable drug exposure between pediatric and adult patients. GEP-NETs are a rare, often late-diagnosed cancer. Novartis is expanding its radioligand therapy portfolio to treat various cancers, including lung, prostate, breast, and more.
April 23, 2024 | 6:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Novartis receives FDA approval for Lutathera, a pioneering treatment for pediatric patients with GEP-NETs, showcasing its leadership in radioligand therapy.
FDA approval of Lutathera for pediatric patients represents a significant milestone for Novartis, potentially boosting its market position and showcasing its commitment to expanding treatment options for rare cancers. This approval could lead to increased interest and investment in Novartis' radioligand therapy portfolio, positively impacting its stock in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100